Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Sponsor
SCRI Development Innovations, LLC
Study ID
NCT00193349
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Imatinib — DRUG
  • Irinotecan — DRUG
  • Carboplatin — DRUG

Study Details

This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.

Key Dates

Start date
Sep 30, 2002
Status verified
Jan 2008
Primary completion
Dec 31, 2007
Completion
Dec 31, 2007

Study Design

Enrollment
60 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Overall response rate

Related Studies